GlaxoSmithKline plans to split into two businesses – one for Rx drugs and vaccines, and the other for OTC products – after forming a new joint venture with Pfizer’s consumer health division.
Shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Ireland’s Shire for about $58 billion.
Elanco Animal Health’s shares climbed 36 percent in their stock market debut, in a sign of investor enthusiasm for the fast-growing pet healthcare market.
Cigna Corp. shareholders voted in favor of the health insurer’s proposed $52 billion acquisition of pharmacy benefit manager Express Scripts Holding Co.
As Shire’s acquisition by Takeda Pharmaceutical approaches, the global biotechnology company reported a solid second-quarter 2018.
Switzerland-based Novartis announced plans to spin off Alcon, its eye care division, into a separately traded standalone company.
More than 35 percent of AstraZeneca shareholders rejected or abstained from supporting an executive pay plan for the U.K.-based pharma giant.
According to Reuters UK, Japan’s Takeda Pharmaceutical made an official bid to acquire London’s Shire for about $60 billion, which was rejected.
Shire, a global biotechnology company focused on rare diseases, sold its oncology business to France’s Servier for $2.4 billion.
Nevada-based PDL BioPharma will no longer pursue a proposed acquisition of Neos Therapeutics. PDL made three failed attempts to acquire Texas-based Neos.